VFV. I. Frolova

V. I. Frolova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


V. I. Frolova has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The experience of using agomelatine (Valdoxan) in the treatment of generalised anxiety disorder

    by V. I. Frolova

    Generalised anxiety disorder (GAD) is one of the most common anxiety disorders worldwide. Without treatment, GAD is characterised by a chronic course and significantly impairs social and occupational functioning. The main method of treating GAD in clinical practice is psychopharmacotherapy. Despite the fact that psychiatrists have a fairly large number of psychotropic drugs at their disposal, which are used in accordance with international and domestic clinical guidelines for the treatment of GAD, a number of therapeutic aspects remained unresolved until recently.In the updated clinical guidelines, agomelatine, an antidepressant that acts on melatonergic (MT1, MT2) and serotonergic (5-HT2C) receptors, was included among the first-line drugs for the treatment of GAD. The efficacy of agomelatine in treating GAD symptoms has been demonstrated in a number of randomised clinical trials. This article presents our own observations, illustrating some aspects of the use of agomelatine in real clinical practice.

  • Dysmorphia with gender identity disorder

    by V.E. Medvedev, Yu.P. Sivolap, V.I. Frolova, E.V. Gushanskaya, S.I. Gushanskiy, N.L. Zuikova, I.V. Salyntsev

    The frequency of comorbidity of body dysmorphic disorder (DD) and gender identification disorder (FIR) is 26.9% -100%. At the same time, the nature of the clinico-dynamic interrelations between dysmorphia and FIR has not been sufficiently studied. Goal: To study the nature of the clinical and dynamic interrelationships of EPI in patients with schizophrenic spectrum disorders. Materials and methods: The study included patients of both sexes aged 18 to 65 years who reported dissatisfaction with their biological sex.Clinical-psychopathological, clinical-catamnestic and statistical research methods were used. Results. In the course of the study, a typological differentiation of TDR with FIR was carried out, which was determined by the structure and dynamics of mental disorders. In all patients, DTP preceded the formation of EPI. In addition to DTP, patients within the framework had depersonalization (68.6%) and autodestructive tendencies (48.6%). In all observations, FIR developed according to the mechanism of a sudden “informational epiphany”, with a reassessment of past events, pseudo-reminiscences and the development of overwhelming ideas of sexual metamorphosis. EPI in patients with schizophrenia is formed within the framework of simple monothematic gender dysmorphia (22.9%) or against the background of complex polythematic dysmorphia with non-feminine emotional-volitional disorders (77.9%) of DD. The further dynamics of the EPI is determined by the course of the schizophrenic process (low-progressive, paroxysmal). Treatment of DTP with FIR is a complex task and is carried out using antidepressants and modern antipsychotics, as well as psychotherapy. Conclusion: The possible influence of mental illness on the clinical and dynamic characteristics of patients necessitates the further study of TDR in outpatient patients with isolated EPI, as well as EPI in other comorbid mental pathologies such as personality disorders, affective disorders, and other disorders.

  • Cariprazine in the treatment of depressive disorders (A Literature Review)

    by Yu.V. Bykov, V.I. Frolova, A.YU. Bykova, R.A. Bekker

    This article examines in detail the importance of depressive disorders in the modern world, the shortcomings and limitations of currently available antidepressants, the theoretical basis for studying cariprazine in the context of treating depression. Then we thoroughly review the available evidence base for the use of cariprazine in the treatment of both bipolar and unipolar depressive disorders, both as an monotherapy and as an antidepressant augmentation.

  • Fluvoxamine in the treatment of anxiety-depressive spectrum disorders

    by V.E. Medvedev, R.A. Kardashian, V.I. Frolova

    The RSCI and PubMed search databases have requested publications over the past 40 years on the search queries «fluvoxamine», «anxiety-depressive disorders», «anxiety», «depression», «comorbidity», devoted to the effectiveness of fluvoxamine in various variants of disorders of the anxiety-depressive spectrum, anxiety depressions. The data of the above studies indicate that fluvoxamine (Zovart San) in doses of 50-300 mg / day is a highly effective remedy for the treatment of not only anxiety depressions and genesis (psychogenic, organic, mixed, autochthonous-endogenous) and severity (up to psychotic), but also a wider range of anxiety-depressive disorders, including adaptation disorders, obsessive-compulsive disorder, somatized, dysmorphic, insomniac symptom complexes and eating disorders. A wide range of clinical effects of fluvoxamine is due to its main and additional mechanisms of action: blockade of serotonin reuptake, σ1-agonist activity and the effect on the metabolism of melatonin and neurosteroids catabolism.


  • Multi-center open comparative randomized study of efficacy and safety of Akatinol Memantine 20 mg (single-doses) vs Akatinol Memantine 10 mg (double-doses) in patients with vascular dementia

    by S.I. Gavrilova, I.V. Kolykhalov, N.M. Mikhaylova, E.V. Ponomareva, Ya.B. Fedorova, V.E. Medvedev, V.I. Frolova, E.V. Gushanskaya, I.V. Litvinenko, A.YU. Emelin, et al.

    OBJECTIVE Evaluation of the efficacy and safety of the drug Acatinol Memantine, 20 mg (once daily) in comparison with the drug Acatinol Memantine, 10 mg (twice daily) in patients with moderate to moderate severe vascular dementia. MATERIAL AND METHODS The study included 130 patients aged 50—85 years of both sexes with instrumentally and clinically confirmed vascular dementia. The patients were randomized into 2 groups. Group I consisted of 65 patients receiving Akatinol Memantine, 20 mg once daily, group II — 65 patients receiving Akatinol Memantine, 10 mg twice daily for 24 weeks. Clinical, parametric and statistical research methods were used. The Alzheimer’s disease assessment scale, the cognitive subscale (ADAS-cog), the short mental Status Assessment Scale (MMSE) and the general clinical impression scale for patients condition and illness severity (CGI-C and CGI-S) and the Hamilton Depression Rating scale (HAM-D) were used. Adverse events were collected and analyzed. RESULTS At week 24, both groups showed statistically significant positive change in ADAS-cog total score: in group I the total score was 27.2±8.76 points (absolute difference from baseline 3.5 points; pp<0.01) with no statistically significant differences between groups. Evaluation of secondary efficacy criteria (change in ADAS-cog total score at week 12 and MMSE at weeks 4, 12, and 24) also revealed statistically significant benefit in both groups compared to baseline with no significant differences between groups. Statistically significant improvement was noticed on CGI-S and CGI-C scales in both groups. Akatinol Memantine was safe and well tolerated in both groups. CONCLUSION The study showed no lesser efficacy and safety of Akatinol Memantine, 20 mg (once daily) compared to Akatinol Memantine, 10 mg (twice daily) in patients with moderate and moderately severe vascular dementia.


  • Optimization of treatment of depression with administration of ethylmethylhydroxypyridine succinate (Mexicor)

    by V.E. Medvedev, V.I. Frolova, A.V. Palin

    ЦЕЛЬ ИССЛЕДОВАНИЯ Изучение терапевтической эффективности и переносимости назначения Мексикора в качестве адъювантного средства при терапии депрессий антидепрессантами из группы селективных ингибиторов обратного захвата серотонина (СИОЗС). МАТЕРИАЛ И МЕТОДЫ В исследование были включены 100 пациентов (возраст 18—50 лет) с верифицированной депрессией легкой (n=32) или средней (n=68) степени тяжести. Пациенты основной группы (n=50) вместе с базовой антидепрессивной терапией СИОЗС получали Мексикор в дозе 600 мг/сут, группы сравнения (n=50) — только СИОЗС. Применялись клинико-психопатологический, психометрический, с использованием шкал HDRS-21, CGI, HADS, теста беглости речевых ответов и теста Струпа, статистический методы исследования. РЕЗУЛЬТАТЫ Редукция депрессивной симптоматики по шкале HDRS-21 начиная с 4-й недели статистически значимо (pppp<0,001). ЗАКЛЮЧЕНИЕ Назначение Мексикора в дозе 600 мг/сут вместе с СИОЗС приводит к повышению эффективности и переносимости антидепрессивной терапии. В перспективе Мексикор может быть рекомендован в качестве адъювантного средства при терапии депрессии СИОЗС.


  • Clinical aspects of the use of imidazopyridine derivatives in the treatment of sleep disorders associated with post-COVID syndrome

    by O.V. Kotova, E.V. Tsareva, V.E. Medvedev, A.A. Belyaev, E.V. Gushanskaya, V.I. Frolova, I.G. Kotelnikova

    В 2019 г. началась пандемия, вызванная вирусом SARS-CoV-2. Борьба с COVID-19 потребовала введения ряда ограничительных мер, в частности карантина для населения и изоляции заболевших, что наряду с непосредственным влиянием вируса на нервную систему привело к значительному распространению нарушений сна. В связи с этим стали актуальными вопросы о выборе препаратов для коррекции нарушений сна, о том, какие снотворные препараты будут безопасны в условиях острого заболевания и в период восстановления после COVID-19. В статье обсуждаются проблемы распространенности и терапии инсомнии у пациентов с острым COVID-19 и с постковидным синдромом (ПКС). Описываются фармакологические эффекты и безопасность золпидема — небензодиазепинового снотворного препарата короткого действия, относящегося к классу имидазопиридинов, который применяют короткими курсами при инсомнии как острой и транзиторной, так и хронической. Приводятся данные о способности золпидема улучшать память после ночного сна. Оценивается возможность его применения при остром COVID-19 и ПКС.

  • Therapy of cardioneurosis with modern antidepressants in general medical care network

    by V. E. Medvedev, V. I. Frolova, O. V. Kotova

    The clinical presentation of cardioneurosis is heterogeneous and includes anxiety-phobic, cenestalgic, and depressive symptoms. General practitioners, who most often see this category of patients, usually recommend to take «sedatives». Modern antidepressant, i. e. selective serotonin reuptake inhibitor, escitalopram demonstrated high efficiency and good tolerability in patients with cardoneurosis (neurocirculatory dystonia).